Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Galmarini

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Scientific Reports|October 8, 2016
Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product PlitidepsinAlejandro Losada, María José Muñoz-Alonso, Carolina García, et al.
Molecular Cancer Therapeutics|May 31, 2011
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cellsDaniele G Soares, Miriana S Machado, Céline J Rocca, et al.
BMC Cancer|February 8, 2017
Mechanism of action of trabectedin in desmoplastic small round cell tumor cellsS Uboldi, I Craparotta, G Colella, et al.
Investigational New Drugs|September 3, 2011
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cellsPablo E Morande, Samanta R Zanetti, Mercedes Borge, et al.
British Journal of Cancer|December 4, 2015
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinB Colmegna, S Uboldi, R Frapolli, et al.
Plos One|October 17, 2015
Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell DeathJosé Manuel Molina-Guijarro, Carolina García, Álvaro Macías, et al.
Molecular Cancer Therapeutics|February 15, 2018
MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing TumorsPablo Avilés, Juan Manuel Domínguez, María José Guillén, et al.
ACS Chemical Biology|July 18, 2013
New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanismBenet Pera, Isabel Barasoain, Areti Pantazopoulou, et al.
Biochemical Pharmacology|February 4, 2014
PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumorsMarta Martínez-Díez, María José Guillén-Navarro, Benet Pera, et al.
British Journal of Pharmacology|October 28, 2010
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activityJ F M Leal, M Martínez-Díez, V García-Hernández, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Scientific Reports|October 8, 2016
Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product PlitidepsinAlejandro Losada, María José Muñoz-Alonso, Carolina García, et al.
Molecular Cancer Therapeutics|May 31, 2011
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cellsDaniele G Soares, Miriana S Machado, Céline J Rocca, et al.
BMC Cancer|February 8, 2017
Mechanism of action of trabectedin in desmoplastic small round cell tumor cellsS Uboldi, I Craparotta, G Colella, et al.
Investigational New Drugs|September 3, 2011
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cellsPablo E Morande, Samanta R Zanetti, Mercedes Borge, et al.
British Journal of Cancer|December 4, 2015
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinB Colmegna, S Uboldi, R Frapolli, et al.
Plos One|October 17, 2015
Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell DeathJosé Manuel Molina-Guijarro, Carolina García, Álvaro Macías, et al.
Molecular Cancer Therapeutics|February 15, 2018
MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing TumorsPablo Avilés, Juan Manuel Domínguez, María José Guillén, et al.
ACS Chemical Biology|July 18, 2013
New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanismBenet Pera, Isabel Barasoain, Areti Pantazopoulou, et al.
Biochemical Pharmacology|February 4, 2014
PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumorsMarta Martínez-Díez, María José Guillén-Navarro, Benet Pera, et al.
British Journal of Pharmacology|October 28, 2010
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activityJ F M Leal, M Martínez-Díez, V García-Hernández, et al.
Pageof 13